Multiparametric magnetic resonance imaging of the prostate - Technique and clinical applications;Multiparametrische magnetresonanztomografie der prostata - Technik und klinische anwendungen

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 183, Issue 7, 2011, Pages 607-617

  Franiel, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

MR diffusion perfusion; MR functional imaging; MR spectroscopy; prostate

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RECURRENT CANCER; REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME;

CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; EARLY DIAGNOSIS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79958769344     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0029-1246055     Document Type: Review

References (72)

1. Bertz J, Dahm S, Haberland J et al. Prostata. In Verbreitung von Krebserkrankungen in Deutschland, Berlin: Robert Koch Institut, 2010: 98-102
2. Schlemmer HP. Multiparametrische MRT der Prostata: Methode zur Früherkennung des Prostatakarzinoms? Fortschr Röntgenstr 2010; 182: 1067-1075
3. Fütterer JJ, Heijmink SW, Scheenen TW et al. Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging. Radiology 2006; 241: 449-458
4. Sciarra A, Panebianco V, Ciccariello M et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16: 1875-1883
5. Lim HK, Kim JK, Kim KA et al. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology 2009; 250: 145-151
6. McNeal JE. Normal and pathologic anatomy of prostate. Urology 1981; 17: 11-16 (Pubitemid 11110408)
7. McNeal JE, Redwine EA, Freiha FS et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906 (Pubitemid 19011040)
8. Mueller-Lisse U, Scheer M. MRT und MR-Spektroskopie der Prostata - praktische Darstellungen. Fortschr Röntgenstr 2009; 181: S122
9. Schlemmer HP. MRT des Prostatakarzinoms. Fortschr Röntgenstr 2010; 182: S96
10. Schlemmer HP. Die MR-Tomographie und MR-Spektroskopie des Prostatakarzinoms. Fortschr Röntgenstr 2009; 181: S50
11. Shukla-Dave A, Hricak H, Moskowitz C et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007; 245: 499-506 (Pubitemid 47612532)
12. Scheidler J, Vogel M, Gross P et al. Combined MRI and MRS in prostate cancer: improvement of spectral quality by susceptibility matching. Fortschr Röntgenstr 2009; 181: 531-535
13. Verma S, Rajesh A, Futterer JJ et al. Prostate MRI and 3D MR spectroscopy: how we do it. Am J Roentgenol 2010; 194: 1414-1426
14. Scheenen T, Weiland E, Fütterer J. et al. Preliminary results of IMAPS: an international multi-centre assessment of proste MR spectroscopy. Presented at:. 13th Scientific Meeting of The International Society for Magnetic Resonance in Medicine. Miami, FL, USA; 2005: 7-13 May 2005.
15. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143-153 (Pubitemid 40823303)
16. Daly PF, Lyon RC, Faustino PJ et al. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 1987; 262: 14875-14878 (Pubitemid 17160163)
17. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echos in the presence of a time dependent field gradient. J Chem Phys 1965; 42: 288-292
18. Mulkern RV, Barnes AS, Haker SJ et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24: 563-568 (Pubitemid 43776563)
19. Le Bihan D, Breton E, Lallemand D et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505
20. Padhani AR, Liu G, Koh DMet al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125
21. Langer DL, van der Kwast TH, Evans AJ et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology 2010; 255: 485-494
22. Mazaheri Y, Shukla-Dave A, Hricak H et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008; 246: 480-488
23. Tamada T, Sone T, Jo Y et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28: 720-726
24. Kim JH, Kim JK, Park BW et al. Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging 2008; 28: 1173-1179
25. Yamamura J, Salomon G, Graessner J et al. MRT des Prostatakarzinoms: Diffusion Weighted Imaging im Vergleich mit der Histologie. Fortschr Röntgenstr 2009; 181: S242
26. Walker-Samuel S, Orton M, McPhail LD et al. Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. Magn Reson Med 2009; 62: 420-429
27. Franiel T. Kontrastmittel-Perfusionsuntersuchungen in der Urogenitalen Radiologie: Vom Modell zur flächendeckenden klinischen Anwendung. Fortschr Röntgenstr 2010; 182: S149
28. Engelbrecht MR, Huisman HJ, Laheij RJ et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-254
29. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232
30. Hoffmann U, Brix G, Knopp MV et al. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995; 33: 506-514
31. Prochnow D, Beyersdorff D, Warmuth C et al. Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magn Reson Imaging 2005; 23: 983-990
32. Tweedle MF, Wedeking P, Telser J et al. Dependence of MR signal intensity on Gd tissue concentration over a broad dose range. Magn Reson Med 1991; 22: 191-194; discussion 195-196
33. Walker-Samuel S, Leach MO, Collins DJ. Reference tissue quantification of DCE-MRI data without a contrast agent calibration. Phys Med Biol 2007; 52: 589-601
34. Cheng HL, Wright GA. Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med 2006; 55: 566-574
35. Parker GJ, Roberts C, Macdonald A et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000
36. Brix G, Semmler W, Port R et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991; 15: 621-628
37. Lüdemann L, Prochnow D, Rohlfing T et al. Simultaneous Quantification of Perfusion and Permeability in the Prostate Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with an Inversion-Prepared Dual-Contrast Sequence. Ann Biomed Eng 2009; 37: 749-762
38. Franiel T, Lüdemann L, Rudolph B et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 2008; 43: 481-487
39. Franiel T, Lüdemann L, Rudolph B et al. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 2009; 252: 101-108
40. Buckley DL, Roberts C, Parker GJ et al. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004; 233: 709-715
41. Riches SF, Payne GS, Morgan VA et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. Am J Roentgenol 2009; 193: 1583-1591
42. van Dorsten FA, van der Graaf M, Engelbrecht MR et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004; 20: 279-287
43. Heijmink SW, Fütterer JJ, Hambrock T et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3T - comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195
44. Beyersdorff D, Taymoorian K, Knosel T et al. MRI of prostate cancer at 1.5 and 3.0T: comparison of image quality in tumor detection and staging. Am J Roentgenol 2005; 185: 1214-1220
45. Tanimoto A, Nakashima J, Kohno H et al. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152
46. Kumar R, Nayyar R, Kumar V et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 2008; 72: 859-863
47. Prando A, Kurhanewicz J, Borges AP et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 903-910
48. Zangos S, Eichler K, Thalhammer A et al. Aktueller Stand der MR-gesteuerten Prostata-Interventionen. Fortschr Röntgenstr 2010; 182: 947-953
49. Franiel T, Stephan C, Erbersdobler A et al. Areas suspicious for prostate cancer: MR-guided biopsy of the prostate in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR Imaging for detection and biopsy planning. Radiology 2011; In Press
50. Hricak H, Wang L, Wei DC et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004; 100: 2655-2663
51. Röthke M, Lichy M, Schilling D et al. Klinische Wertigkeit der endorektalen MRT vor geplanter nerverhaltender radikaler Prostatektomie. Fortschr Röntgenstr 2009; 181: S243
52. Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004; 64: 101-105
53. Zakian KL, Sircar K, Hricak H et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814
54. Bloch BN, Furman-Haran E, Helbich TH et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology 2007; 245: 176-185
55. Yu KK, Scheidler J, Hricak H et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213: 481-488
56. Wang L, Hricak H, Kattan MW et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238: 597-603
57. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 281-286
58. Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004; 231: 379-385
59. Pucar D, Hricak H, Shukla-Dave A et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007; 69: 62-69
60. Coakley FV, Teh HS, Qayyum A et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233: 441-448
61. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3 T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 391-397
62. Haider MA, Chung P, Sweet J et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 425-430
63. Sciarra A, Panebianco V, Salciccia S et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008; 54: 589-600
64. Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009; 19: 761-769
65. Shukla-Dave A, Hricak H, Eberhardt SC et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings - initial observations. Radiology 2004; 231: 717-724
66. Kulkarni GS, Lockwood G, Evans A et al. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007; 109: 2432-2438
67. Franiel T, Lüdemann L, Taupitz M et al. Pharmakokinetische MRT der Prostata: Parameter zur Unterscheidung von Low-grade- und Highgrade- Prostatakarzinomen. Fortschr Röntgenstr 2009; 181: 536-542
68. D'Amico AV, Chang H, Holupka E et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997; 49: 385-391
69. Coakley FV, Kurhanewicz J, Lu Y et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223: 91-97
70. Mazaheri Y, Hricak H, Fine SW et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252: 449-457
71. Zhang J, Hricak H, Shukla-Dave A et al. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009; 253: 425-434
72. Shukla-Dave A, Hricak H, Kattan MW et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99: 786-793